Breakthrough with innovative imaging diagnostics and targeted therapy of heart fibrosis (Q3988804): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Fixing summary) |
(Changed an Item: Adding English translations) |
||||||||||||||
| Property / summary | |||||||||||||||
More and more patients survive the first acute phase of myocardial infarction (MI) but develop chronic heart failure in the following years. This disabling and ultimately fatal disease is caused by diffuse fibrosis (scar tissue) in response to the damage to the heart. BiOrion develops innovative medicinal products to accurately visualise the scar tissue in the heart and then treat it in a targeted way, also showing the effect of that treatment. In this project, BiOrion mainly wants to test the imaging diagnostics it has developed in heart patients. In parallel, a new medicine for fibrosis is produced and tested for safety. If these results are as promising in patients as in animal models, this technology will deliver two new products that will be further developed for the market that can help many millions of patients worldwide. (English) | |||||||||||||||
| Property / summary: More and more patients survive the first acute phase of myocardial infarction (MI) but develop chronic heart failure in the following years. This disabling and ultimately fatal disease is caused by diffuse fibrosis (scar tissue) in response to the damage to the heart. BiOrion develops innovative medicinal products to accurately visualise the scar tissue in the heart and then treat it in a targeted way, also showing the effect of that treatment. In this project, BiOrion mainly wants to test the imaging diagnostics it has developed in heart patients. In parallel, a new medicine for fibrosis is produced and tested for safety. If these results are as promising in patients as in animal models, this technology will deliver two new products that will be further developed for the market that can help many millions of patients worldwide. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: More and more patients survive the first acute phase of myocardial infarction (MI) but develop chronic heart failure in the following years. This disabling and ultimately fatal disease is caused by diffuse fibrosis (scar tissue) in response to the damage to the heart. BiOrion develops innovative medicinal products to accurately visualise the scar tissue in the heart and then treat it in a targeted way, also showing the effect of that treatment. In this project, BiOrion mainly wants to test the imaging diagnostics it has developed in heart patients. In parallel, a new medicine for fibrosis is produced and tested for safety. If these results are as promising in patients as in animal models, this technology will deliver two new products that will be further developed for the market that can help many millions of patients worldwide. (English) / qualifier | |||||||||||||||
point in time: 15 December 2021
| |||||||||||||||
Revision as of 06:19, 15 December 2021
Project Q3988804 in Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Breakthrough with innovative imaging diagnostics and targeted therapy of heart fibrosis |
Project Q3988804 in Netherlands |
Statements
0.0 Euro
0 references
0.0 Euro
0 references
37.85 percent
0 references
1 November 2017
0 references
31 December 2019
0 references
BiOrion Technologies BV
0 references
53°13'11.21"N, 6°34'39.68"E
0 references
9713 GX
0 references
Steeds meer patiënten overleven de eerste acute fase van een hartinfarct (myocardinfarct, MI) maar ontwikkelen juist in de jaren daarna chronisch hartfalen. Deze invaliderende en uiteindelijk dodelijke ziekte wordt veroorzaakt door diffuse fibrose (littekenweefsel) als reactie op de schade aan het hart. BiOrion ontwikkelt innovatieve (genees)middelen om het littekenweefsel in het hart nauwkeurig in beeld te brengen en vervolgens gericht te behandelen, waarbij ook het effect van die behandeling in beeld worden gebracht. In dit project wil BiOrion voornamelijk de door haar ontwikkelde beeldvormende diagnostiek bij hartpatiënten testen. Parallel daaraan wordt een nieuw geneesmiddel voor fibrose geproduceerd en getest op veiligheid. Indien die resultaten bij patiënten net zo veelbelovend als bij de diermodellen, zal deze technologie twee nieuwe producten opleveren die verder worden ontwikkeld voor de markt waar wereldwijd vele miljoenen patiënten mee kunnen worden geholpen. (Dutch)
0 references
More and more patients survive the first acute phase of myocardial infarction (MI) but develop chronic heart failure in the following years. This disabling and ultimately fatal disease is caused by diffuse fibrosis (scar tissue) in response to the damage to the heart. BiOrion develops innovative medicinal products to accurately visualise the scar tissue in the heart and then treat it in a targeted way, also showing the effect of that treatment. In this project, BiOrion mainly wants to test the imaging diagnostics it has developed in heart patients. In parallel, a new medicine for fibrosis is produced and tested for safety. If these results are as promising in patients as in animal models, this technology will deliver two new products that will be further developed for the market that can help many millions of patients worldwide. (English)
15 December 2021
0 references
Identifiers
OP-2014-2023-Noord-OPSNN0177
0 references